Effect Of Different Lining Materials in Stepwise Excavation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Deep carious lesions will encounter the dentist with the challenge of selecting a treatment method that could avoid the pulpal exposure and maintain the pulp vitality.Conventional restorative treatments suggest complete removal of the caries in one visit which could cause pulpal exposure in 53% of the cases which in next step needs pulpotomy, pulpectomy or Root Canal Therapy (RCT).
Stepwise Excavation(SE)is an old concept but has been researched recently to reduce the possibility pulpal exposure during the removal of the lesion. Contrary to Indirect Pulp Capping (IPC), in this technique only the central infected part of the caries is removed in first visit and the rest of the caries will be lined by a suitable material to suppress the remained cariogenic biomass and seal the cavity. This will help the pulp to defend and survive. After a period, the cavity is re-opened and the rest of the caries which is darker, harder and with less bacteria will be removed and the tooth is restored permanently.The aim of this study was to compare the effect of different lining materials in clinical and radiographical symptoms in stepwise excavation without re-enter after one year.
| Condition | Intervention | Phase |
|---|---|---|
|
Dental Pulp Necrosis |
Drug: Control Drug: Calcium Hydroxide Drug: Mineral Trioxide Aggregate(MTA) Drug: CEM cement |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Effect Of Different Lining Materials on Clinical Symptoms of Stepwise Excavation Without Re-enter: Double Blind Randomizd Clinical Trial |
- Pulpal Vitality [ Time Frame: One year ] [ Designated as safety issue: No ]Clinical symptoms, radiographic evaluation. Sensitivity to cold, hot, pressure, percussion.
| Estimated Enrollment: | 100 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | May 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Control
No lining applied in group1.
|
Drug: Control
The teeth in this group restored only by filling material,without liner application.
Other Name: NO liner applied.
|
|
Experimental: CEM cement
CEM cement applied over remained caries in group4.
|
Drug: CEM cement
CEM cement applied .
Other Name: CEM cement, Yektazist,Iran.
|
|
Experimental: Mineral Trioxide Aggregate (MTA)
MTA applied over remained caries in group3.
|
Drug: Mineral Trioxide Aggregate(MTA)
MTA applied .
Other Name: MTA, white MTA, ProRoot,Dentsply.
|
|
Experimental: Calcium Hydroxide
Calcium Hydroxide applied over remained caries in group2.
|
Drug: Calcium Hydroxide
Calcium Hydroxide paste applied.
Other Name: Calcium Hydroxide paste , Dycal,Dentsply.
|
Detailed Description:
In this randomized clinical trial of 4 lining materials have been applied in deep caries teeth in stepwise excavation. The common material which is applied as a liner over the remained caries in SE is Calcium Hydroxide(CH). There are several reports of the solubility of this liner over time which could interact with sealing of the cavity in long term. It seems that a material with antibacterial activity, good sealing ability and suitable mechanical properties could cause SE be done efficiently with good prognosis.
MTA is a biomaterial that has been introduced since 1993 with antibacterial property and good sealing ability. A New Endodontic Cement, Calcium Enriched Mixture (CEM) cement with good antibacterial effect like CH with sealing ability that is proposed to be similar to MTA according to its double sealing property. CEM cement has been suggested as a suitable material in pulp capping of permanent molars with irreversible pulpitis.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
A tooth with deep caries lesion - Tooth at risk of pulpal exposure - No pulpal , instantaneous , night pain
Exclusion Criteria:
Unbearable pain of the involved tooth- Apical radiolucency of the tooth- PDL widening
Contacts and Locations| Contact: Sepideh Banava, Assist-prof | 982188882321 | sbanava@yahoo.com |
| Contact: Mohammad Safaie Yazdi, Dentist | 00989123614034 | mohammad.safaei@yahoo.com |
| Iran, Islamic Republic of | |
| Azad University of Medical Sciences, Dental Branch | Recruiting |
| Tehran, N/A = Not Applicable, Iran, Islamic Republic of, 1517884111 | |
| Contact: Sepideh Banava, Assist-Prof 982188882321 sbanava@yahoo.com | |
| Contact: Mohammad Safaie Yazdi, Dentist 00989123614034 mohammad.safaei@yahoo.com | |
| Principal Investigator: Sepideh Banava, Assist-Prof | |
| Study Chair: | Sepideh Banava, Assist-Prof | Azad University of Medical Sciences, Dental Branch - Endodontics research center , SBMU |
More Information
No publications provided
| Responsible Party: | Sepideh Banava.DDS,MS, Assist-Prof, Azad University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01730287 History of Changes |
| Other Study ID Numbers: | AZadUMS- |
| Study First Received: | November 15, 2012 |
| Last Updated: | November 20, 2012 |
| Health Authority: | Iran: Ethics Committee |
Keywords provided by Azad University of Medical Sciences:
|
Stepwise Excavation Pulpal vitality Deep caries lesions Clinical symptoms Radiographic evaluation |
Additional relevant MeSH terms:
|
Dental Pulp Necrosis Necrosis Dental Pulp Diseases Tooth Diseases Stomatognathic Diseases Pathologic Processes Calcium, Dietary Pemetrexed Bone Density Conservation Agents |
Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Antimetabolites, Antineoplastic Antimetabolites |
ClinicalTrials.gov processed this record on May 21, 2013